Prostate cancer in Port Harcourt, Nigeria: features and outcome

An overview of cancer of the prostate diagnosis and management in Nigeria: The experience in a Nigerian tertiary hospital

“…The present study is in support of this trend and Outcome corroborates the finding of other investigators in our environment, [7][8][9][10][11] with about 700% increase in the incidence between 1997 and 2006. However, a prospective study would be needed to ascertain if the increased incidence seen in this study is apparent from increase in diagnosis or a real increase in the incidence as being documented in literature.…”

“…[8] The mean age as well as the peak age incidence is comparable to reports from this subregion and elsewhere. [1,[6][7][8][9][10][11] Although our youngest patient was 47 years old, investigators from Zaria reported CaP in a 37-year-old patient, Mbibu et al (Personal communication).…”

“…However, a prospective study would be needed to ascertain if the increased incidence seen in this study is apparent from increase in diagnosis or a real increase in the incidence as being documented in literature. This becomes important because the probable reasons earlier adduced for this trend which include increased awareness of the disease, better documentation, increased use of PSA and needle biopsy in the evaluation of men presenting with lower urinary tract symptoms (LUTS) [8,10] are difficult to be substantiated and thus cannot be generalized.…”

“…In our environment, patients often present very late and the treatment options are limited and most often are palliative. [6][7][8][9][10][11][12] We review our experience with CaP management over a 10-year period to highlight the mode of presentation, method of diagnosis, treatment, and the outcome.…”

“…[5] Several studies have documented a progressive increase in the incidence of CaP in Nigeria and West Africa subregion in the recent times. [6][7][8][9][10][11][12] The prognosis of CaP depends on the stage of the disease, the grade or biologic behavior of the malignant cells, and the modalities of treatment. In our environment, patients often present very late and the treatment options are limited and most often are palliative.…”